Investigating Torsin‐1A‐interacting protein 1 as a predictive and immunological biomarker in cancer

Abstract

AbstractBackgroundCancer poses a significant global challenge, and with the projected rise in cancer incidence, there is an urgent need to discover new targets and treatments to improve patient outcomes. Recent advancements in genomics technologies have enhanced our understanding of cancer's complexities and led to the emergence of pan‐cancer analysis as a valuable approach for identifying tumor targets. Torsin‐1A‐interacting protein 1 (TOR1AIP1) is a membrane protein involved in various cellular processes. Emerging evidence suggests its potential involvement in cancer.MethodsIn this study, we conducted a comprehensive analysis of multiple databases to explore TOR1AIP1 expression across different cancer types and stages. We also investigated its correlation with clinical outcomes, such as survival rates and drug sensitivity.ResultsThe results of our analysis showed significant deregulation of TOR1AIP1 expression in multiple cancer types and its association with clinical outcomes, with a particular emphasis on kidney renal clear cell carcinoma. The results of our study highlight the potential predictive value of TOR1AIP1 in cancer prognosis and therapy.ConclusionsThis study establishes a solid foundation and rationale for future experimental investigations, which will contribute to a deeper understanding of the significance of TOR1AIP1 in different cancer types, specifically in kidney renal clear cell carcinoma.